In 2 recent randomized controlled trials, MARINA (the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration)[2] and the ANCHOR study (Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration) [3], it prevented vision loss and improved visual acuity. Here, VEGFA is linked to age-related macular degeneration.